Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SLC-391 |
Trade Name | |
Synonyms | SLC391|SLC 391 |
Drug Descriptions |
SLC-391 is an Axl inhibitor that blocks the phosphotransferase activity of Axl, which potentially stimulates anti-tumor immune response and reverses immunosuppression leading to tumor growth inhibition (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148). |
DrugClasses | AXL Inhibitor 30 |
CAS Registry Number | NA |
NCIT ID | C173362 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Pembrolizumab + SLC-391 | Pembrolizumab SLC-391 | 0 | 1 |
SLC-391 | SLC-391 | 0 | 1 |
SLC-391 + unspecified PD-1 antibody | SLC-391 unspecified PD-1 antibody | 0 | 0 |